{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:21:43Z","timestamp":1784856103086,"version":"3.55.0"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,3,22]],"date-time":"2012-03-22T00:00:00Z","timestamp":1332374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>The primary objective was to investigate the efficacy of desmopressin orally disintegrating tablet versus placebo in patients with nocturia. Pharmacodynamics, safety and patient\u2010reported quality of life (QoL) outcomes were also evaluated. One of several benefits of the new formulation is increased bioavailability. Exploring lower doses allows for a better evaluation of therapeutic effect versus tolerability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a 4\u2010week, randomized, double\u2010blind study comparing 10, 25, 50, or 100\u2009\u00b5g desmopressin versus placebo in adults with defined nocturia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The intent to treat population comprised 757 patients experiencing \u223c3 voids\/night and a high prevalence of nocturnal polyuria (\u223c90%). Increasing doses of desmopressin were associated with decreasing numbers of nocturnal voids and voided volume, greater proportions of subjects with &gt;33% reduction in nocturnal voids, and increased duration of first sleep period. The lowest dose reaching statistical significance (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05 vs. placebo) varied by endpoint. Improvements were clinically meaningful, meaning that patients actually had fewer nightly voids. Post hoc analyses by gender suggested a lower minimum effective dose for women. Desmopressin was generally well tolerated. Reductions in serum sodium to &lt;125\u2009mmol\/L in six women (taking &gt;25\u2009\u00b5g desmopressin) and two men (aged 67 and 82) taking 100\u2009\u00b5g, support lower and gender\u2010specific dosing to reduce the small but clinically significant risk of hyponatraemia. Each void reduced\/hour of sleep gained was associated with significant improvements in QoL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Desmopressin orally disintegrating tablet is an effective and well\u2010tolerated treatment for patients with nocturia. Further exploration of the lower dose range is warranted. Neurourol. Urodynam. 31:441\u2013447, 2012. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.22243","type":"journal-article","created":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T11:21:44Z","timestamp":1332501704000},"page":"441-447","source":"Crossref","is-referenced-by-count":102,"title":["Desmopressin orally disintegrating tablet effectively reduces nocturia: Results of a randomized, double\u2010blind, placebo\u2010controlled trial"],"prefix":"10.1002","volume":"31","author":[{"given":"Jeffrey P.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman R.","family":"Zinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarke M.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Peter","family":"N\u00f8rgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,22]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10053"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.04.011"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20022"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.10.054"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2010.03.002"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2008.02246.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09972.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1991.tb00320.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65572-1"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.09.037"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04683.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.12.018"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20437"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2002.02791.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1067\/S0002-9378(03)00593-3"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000136203.76320.f6"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.01.027"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20168"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X280473"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1993.tb55566.x"},{"key":"e_1_2_7_22_2","first-page":"1159.24","article-title":"Gonadal hormone regulation of the renal vasopressin V2 receptor","volume":"22","author":"Liu J","year":"2008","journal-title":"FASEB J"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.2001.91.4.1893"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00214189"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03479"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00741.2010"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.10.019"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10175.x"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.22243","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.22243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T19:01:05Z","timestamp":1696878065000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.22243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,22]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1002\/nau.22243"],"URL":"https:\/\/doi.org\/10.1002\/nau.22243","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,22]]}}}